Abstract: Junction-isolated blocking voltage devices and methods of forming the same are provided. In certain implementations, a blocking voltage device includes an anode terminal electrically connected to a first p-well, a cathode terminal electrically connected to a first n-well, a ground terminal electrically connected to a second p-well, and an n-type isolation layer for isolating the first p-well from a p-type substrate. The first p-well and the first n-well operate as a blocking diode. The blocking voltage device further includes a PNPN silicon controlled rectifier (SCR) associated with a P+ region formed in the first n-well, the first n-well, the first p-well, and an N+ region formed in the first p-well. Additionally, the blocking voltage device further includes an NPNPN bidirectional SCR associated with an N+ region formed in the first p-well, the first p-well, the n-type isolation layer, the second p-well, and an N+ region formed in the second p-well.

Abstract: An apparatus for transceiver signal isolation and voltage clamp from transient electrical events includes a bi-directional protection device comprising a bipolar PNPNP device assembly, a first parasitic PNPN device assembly, and a second parasitic PNPN device assembly. The bipolar PNPNP device assembly includes an NPN bi-directional bipolar transistor, a first PNP bipolar transistor, and a second PNP bipolar transistor, and is configured to receive a transient voltage signal through first and second pads. The first and second pads are electrically connected to the PNPNP device assembly through emitters of the first and second PNP bipolar transistors. The bipolar PNPNP device assembly is electrically connected to a first parasitic PNPN device assembly comprising a parasitic PNP bipolar transistor and a first parasitic NPN bipolar transistor.

Abstract: Junction-isolated blocking voltage devices and methods of forming the same are provided. In certain implementations, a blocking voltage device includes an anode terminal electrically connected to a first p-well, a cathode terminal electrically connected to a first n-well, a ground terminal electrically connected to a second p-well, and an n-type isolation layer for isolating the first p-well from a p-type substrate. The first p-well and the first n-well operate as a blocking diode. The blocking voltage device further includes a PNPN silicon controlled rectifier (SCR) associated with a P+ region formed in the first n-well, the first n-well, the first p-well, and an N+ region formed in the first p-well. Additionally, the blocking voltage device further includes an NPNPN bidirectional SCR associated with an N+ region formed in the first p-well, the first p-well, the n-type isolation layer, the second p-well, and an N+ region formed in the second p-well.

Abstract: Junction-isolated blocking voltage devices and methods of forming the same are provided. In certain implementations, a blocking voltage device includes an anode terminal electrically connected to a first p-well, a cathode terminal electrically connected to a first n-well, a ground terminal electrically connected to a second p-well, and an n-type isolation layer for isolating the first p-well from a p-type substrate. The first p-well and the first n-well operate as a blocking diode. The blocking voltage device further includes a PNPN silicon controlled rectifier (SCR) associated with a P+ region formed in the first n-well, the first n-well, the first p-well, and an N+ region formed in the first p-well. Additionally, the blocking voltage device further includes an NPNPN bidirectional SCR associated with an N+ region formed in the first p-well, the first p-well, the n-type isolation layer, the second p-well, and an N+ region formed in the second p-well.

Abstract: The invention provides a new kind of dihydroindene amide compounds of general formula I or their pharmaceutically acceptable salts or prodrug thereof which can be used as protein kinase inhibitor. The invention provides a preparation method of the kind of compounds, the pharmaceutical compositions containing the compounds, the method for preventing or curing the diseases related to the abnormity of activities of protein kinases, especially Abl, Bcr-Abl, c-Kit and PDGFR, using them as protein kinase inhibitor, and their preparation use of drug used for preventing or curing the diseases related to the abnormity of activities of protein kinases, especially Abl, Bcr-Abl, c-Kit and PDGFR.

Abstract: The invention provides a new kind of dihydroindene amide compounds of general formula I or their pharmaceutically acceptable salts or prodrug thereof which can be used as protein kinase inhibitor. The invention provides a preparation method of the kind of compounds, the pharmaceutical compositions containing the compounds, the method for preventing or curing the diseases related to the abnormity of activities of protein kinases, especially Abl, Bcr-Abl, c-Kit and PDGFR, using them as protein kinase inhibitor, and their preparation use of drug used for preventing or curing the diseases related to the abnormity of activities of protein kinases, especially Abl, Bcr-Abl, c-Kit and PDGFR.

Abstract: The present invention features methods for increasing levels of nuclear export of mRNA by providing recombinant mammalian export factor. Also featured are methods for preparing metazoan or mammalian cells with recombinant factor ALY that are useful for facilitating mRNA export. The export factor ALY binds mRNA in a non sequence specific manner and the ALY-mRNA complex is exported more efficiently than unbound mRNA. The addition of excess ALY to metazoan or mammalian cell results in increased mRNA export, increased gene expression and increased production of recombinant proteins.

Abstract: The activity of NF-&kgr;B is modulated through the effects of GSK-3 on NF-&kgr;B activity. Inhibition or down-regulation of GSK-3 results in decreased NF-&kgr;B activity. Inappropriate activation of NF-&kgr;B has been linked to inflammation and hyperproliferative disorders. Development of modulatory strategies provide a novel therapeutic tool for the treatment or prevention of various diseases. Methods are also provided for enhanced killing of tumor cells through the sensitization action of GSK-3 inhibition, when administered in conjunction with apoptosis inducing ligands of TNFR1. Transgenic animals defective in GSK-3 function are also provided.